Senior leaders at Celldex Therapeutics, including multiple SVPs, have completed substantial transactions involving company shares, signaling potential confidence or strategic positioning amid ongoing clinical and commercial developments.
- Five SVPs at Celldex Therapeutics sold a combined 252,400 shares in a 30-day window.
- Total proceeds from the transactions amounted to approximately $12.3 million.
- Average stock price during the period was $48.72, based on publicly available trading data.
- Executives involved include senior leaders in clinical development and business strategy.
- Transactions occurred amid pending Phase 3 data readouts and a scheduled investor event on February 15, 2026.
- Insider trading volume exceeds typical levels for the company in recent quarters.
Senior vice presidents at Celldex Therapeutics have collectively engaged in a series of notable stock transactions, with filings revealing the sale of over 250,000 shares in the past 30 days. The transactions, disclosed under SEC Form 4, involved five distinct executives, including the SVP of Clinical Development and the SVP of Business Development. Together, the sales totaled approximately $12.3 million in proceeds, based on the average closing price of CLDX stock during the period. These moves follow a period of regulatory updates and ongoing Phase 3 trial data readouts for the company’s lead oncology candidate, CDX-0159. The volume of activity is particularly noteworthy given the company’s current market capitalization of around $380 million and its reliance on milestone-driven partnerships and investor support. While the filings do not indicate intent behind the trades, such movements by senior leadership can influence market perception, particularly in biotech firms where insider behavior is closely watched by institutional and retail investors. The timing coincides with the company’s upcoming investor day scheduled for February 15, 2026, where additional data and pipeline updates are expected.